Table 3 Information on disease activity, physical function and use of bDMARDs during 6 years of follow-up

1.625 ^b

(1.031–2.094)

n = 72

1.375

(0.625–2.0) n = 52

1.125

(0.594–1.875) n = 50

1.0 ^a

(0.625–1.843) n = 48

1.125

(0.87–1.812) n = 49

1.25

(0.8 a 1.625) n = 43

1.187

(0.84–1.875) n = 30

15.9 ^b

(11.4–22.1)

n = 57

12.8

(5.6–18.6) n = 47

10.9

(5.8–16.4) n = 50

13.8

(8.0–19.1) n = 45

11.6 ^a

(7.1–17.1) n = 48

14.1

(8.3–19.9) n = 40

15.0

(9.4–22.1) n = 28

8 ^a (11,1%)

n = 72

8 ^a (14,5%) n = 55

18 ^b (34%) n = 53

20 ^b (41,7%) n = 48

20 ^b (40%) n = 50

13 (31%) n = 42

9 (29%) n = 42